DPP-4 Inhibitors: REMS Programs, Safe Handling, and What Women Need to Know

What a REMS Is, and Why DPP-4 Inhibitors Do Not Have One

A Risk Evaluation and Mitigation Strategy is an FDA-mandated safety program for drugs whose benefits are judged to outweigh risks only when specific safeguards are in place. Think thalidomide, isotretinoin, or clozapine: drugs where dispensing without strict controls would cause predictable serious harm. The FDA maintains a current list of all active REMS programs, and as of January 2025, no DPP-4 inhibitor appears on that list.

That absence does not mean the class is risk-free.

Why the Absence of a REMS Can Be Misleading

A drug without a REMS still carries labeling warnings. DPP-4 inhibitors have accumulated post-marketing safety signals serious enough to alter prescribing practice, particularly for women managing type 2 diabetes (T2D) alongside hormonal conditions. The FDA has issued multiple label updates since the first agent, sitagliptin, was approved in 2006.

The REMS Threshold and Where DPP-4 Inhibitors Fall

Under the Food and Drug Administration Amendments Act of 2007, a REMS is required when a drug's serious risks cannot be adequately communicated through standard labeling alone. For DPP-4 inhibitors, the FDA determined that label warnings, medication guides, and post-marketing studies were sufficient to communicate the risks. That determination is based on the overall safety profile: low hypoglycemia rate when used without sulfonylureas or insulin, no narrow therapeutic index, and no teratogenic signal requiring mandatory contraceptive programs.

Real Risks That Require Careful Handling Even Without a REMS

Pancreatitis: The Highest-Priority Signal

The FDA added a pancreatitis warning to all DPP-4 inhibitor labels following post-marketing reports. A 2013 FDA drug safety communication described an investigation into reports of pancreatitis and pre-cancerous pancreatic cell changes with incretin-based therapies including DPP-4 inhibitors.

For women, this matters in two specific ways. First, women have a baseline higher rate of gallstone-related pancreatitis than men, particularly during reproductive years and postpartum. Second, if you are taking a DPP-4 inhibitor alongside estrogen-containing contraception or hormone therapy, estrogen independently raises triglycerides and gallstone risk. That combination does not create a REMS-level contraindication, but it does warrant discussing your full medication list with your prescriber.

Stop taking the drug and contact your provider immediately if you develop persistent severe abdominal pain, especially pain that radiates to your back.

Saxagliptin and Heart Failure Hospitalization

This is the most consequential safety finding the class has generated. The SAVOR-TIMI 53 trial, published in the New England Journal of Medicine in 2013, randomized 16,492 patients with T2D and established or high-risk cardiovascular disease to saxagliptin versus placebo. The primary cardiovascular outcome was neutral: saxagliptin neither reduced nor increased MACE. The signal that changed labeling was an increase in heart failure hospitalization: 3.5% of saxagliptin patients were hospitalized for heart failure compared with 2.8% in the placebo group (hazard ratio 1.27, 95% CI 1.07 to 1.51).

The FDA updated the saxagliptin (Onglyza) and alogliptin (Nesina) labels in 2016 to include this finding. The label now states that saxagliptin should be used with caution in patients at risk for heart failure or with existing heart failure.

Women with heart failure are often under-diagnosed relative to men, partly because preserved-ejection-fraction heart failure (HFpEF) is more common in women. If you have unexplained shortness of breath, ankle swelling, or exercise intolerance, this label warning is clinically relevant to you regardless of whether a formal REMS program exists.

Bullous Pemphigoid: A Skin Condition More Common in Older Women

Post-marketing surveillance identified an association between DPP-4 inhibitors and bullous pemphigoid, a blistering autoimmune skin condition. A 2018 FDA drug safety communication and subsequent label updates describe cases that required hospitalization. Bullous pemphigoid predominantly affects adults over age 60, a population that overlaps substantially with post-menopausal women on DPP-4 inhibitors.

If you develop blisters or skin erosions anywhere on your body while taking any DPP-4 inhibitor, this needs dermatological evaluation promptly. Discontinuing the drug often leads to resolution, though some patients require immunosuppressive treatment.

Severe Joint Pain (Arthralgia)

A 2015 FDA safety communication added a warning about disabling and severe joint pain associated with DPP-4 inhibitors. This can occur within days of starting or after years of use. The joint pain resolves in most patients when the drug is discontinued.

Women in perimenopause and post-menopause already experience musculoskeletal complaints as estrogen falls; the joint pain associated with DPP-4 inhibitors can be mistaken for menopausal arthralgia. Temporal relationship to starting or dose-changing the drug is your best diagnostic clue.

DPP-4 Inhibitors Across the Female Life Stages

Reproductive Years and PCOS

Polycystic ovary syndrome (PCOS) drives insulin resistance in a majority of affected women, which makes T2D second-line agents worth examining in this population. A 2018 randomized controlled trial published in Fertility and Sterility compared sitagliptin with metformin in women with PCOS and found that sitagliptin produced comparable reductions in fasting insulin and testosterone with a more favorable gastrointestinal side-effect profile.

DPP-4 inhibitors are not FDA-approved for PCOS. If you are prescribed one off-label for insulin resistance in PCOS, contraception discussions are mandatory because of the pregnancy considerations below.

Trying to Conceive

If you are actively trying to conceive, DPP-4 inhibitors should be discontinued before conception is attempted. The reproductive endocrinology principle is conservative: switch to agents with more reassuring human safety data (metformin) or, once pregnant, to insulin. Discuss this transition with your endocrinologist at least one to two full menstrual cycles before planned conception.

Perimenopause

Perimenopause, the years of hormonal flux before the final menstrual period, carries its own metabolic shift. Estrogen withdrawal reduces insulin sensitivity, and many women develop impaired glucose tolerance or overt T2D during this period for the first time. Data from the Study of Women's Health Across the Nation (SWAN) showed that the transition to menopause is associated with increases in fasting glucose and insulin resistance independent of weight gain.

DPP-4 inhibitors are weight-neutral, which makes them attractive choices for perimenopausal women who are already managing weight concerns. They do not interact pharmacokinetically with standard hormone therapy formulations, and no dose adjustment is required based on menopausal status alone. Renal function matters more: linagliptin is the only agent that does not require dose reduction in chronic kidney disease because it is excreted primarily by the liver.

A practical framework for choosing among DPP-4 inhibitors in perimenopausal women with T2D:

| Situation | Preferred Agent | Reason | |-----------|----------------|--------| | CKD stage 3b or worse | Linagliptin | No renal dose adjustment | | Heart failure risk or diagnosis | Avoid saxagliptin; consider linagliptin or sitagliptin | SAVOR-TIMI 53 signal | | Age >60 with skin fragility | Monitor closely for bullous pemphigoid | Post-marketing signal | | Concurrent hormone therapy | Any agent; watch triglycerides if oral estrogen | Pancreatitis risk additive | | On systemic corticosteroids | Any DPP-4 inhibitor works; glucose-lowering modestly effective | Steroid-induced hyperglycemia |

Post-Menopause

Bone health is a critical consideration in post-menopausal women, and some data suggest DPP-4 inhibitors may have a neutral or mildly favorable effect on bone compared with thiazolidinediones. A meta-analysis published in JAMA Internal Medicine in 2015 found no significant increase in fracture risk with DPP-4 inhibitor use. This is clinically relevant because post-menopausal women with T2D already carry elevated fracture risk from both the disease itself and the hormonal changes of menopause.

Pregnancy and Lactation Safety

Pregnancy: Avoid DPP-4 Inhibitors

DPP-4 inhibitors are not recommended during pregnancy. The evidence is thin but concerning enough to prompt caution.

Animal reproductive studies with sitagliptin showed no teratogenicity at clinical doses, but human data are limited to case reports and small registry studies. The FDA assigned DPP-4 inhibitors to Pregnancy Category B before the category system was retired, meaning animal data showed no harm but adequate human studies were lacking. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the labels now state: there are no adequate and well-controlled studies in pregnant women.

The American College of Obstetricians and Gynecologists (ACOG) and most endocrinology guidelines recommend insulin as the first-line pharmacologic agent for diabetes management in pregnancy. Metformin may be used as an adjunct in selected situations, but DPP-4 inhibitors are not part of standard gestational diabetes management.

If you are diagnosed with gestational diabetes or find yourself pregnant while taking a DPP-4 inhibitor, contact your OB-GYN or maternal-fetal medicine provider immediately to transition to insulin.

Lactation: Insufficient Data

No DPP-4 inhibitor has been adequately studied in lactating women. Animal studies with sitagliptin have shown excretion in breast milk, and because neonates and infants cannot regulate their own glucose as well as adults, even mild DPP-4 inhibition from drug transfer could theoretically cause harm. The prescribing information for all approved agents states that the decision to breastfeed or continue the drug should account for the importance of breastfeeding to the woman and the potential for drug exposure in the infant.

In practice, the conservative clinical recommendation is to use a different agent or to pump and discard during treatment. Discuss your breastfeeding goals explicitly with your prescriber rather than assuming either choice is mandatory.

Contraception Requirements

DPP-4 inhibitors are not teratogenic in the way that isotretinoin or valproate are. There is no mandatory contraception program. However, given that the drug should be discontinued before conception, any woman of reproductive age using a DPP-4 inhibitor off-label for PCOS or on-label for T2D should have an active contraceptive plan if she is not actively trying to conceive. This is a clinical best practice, not a REMS-mandated requirement.

Who This Medication Is Right For, and Who Should Look at Other Options

DPP-4 Inhibitors Are a Reasonable Choice If You Are

• A woman with T2D who cannot tolerate metformin's gastrointestinal side effects and needs a second-line option
• Post-menopausal with moderate chronic kidney disease (CKD stage 3a or 3b), where linagliptin requires no dose reduction
• Concerned about hypoglycemia in an active lifestyle (DPP-4 inhibitors are essentially hypoglycemia-free when used without insulin or sulfonylureas)
• Managing T2D alongside a condition that makes weight gain from thiazolidinediones unacceptable
• Taking this off-label under specialist supervision for PCOS-related insulin resistance

Reconsider or Avoid If You Are

• Pregnant or planning pregnancy in the next one to two menstrual cycles
• Breastfeeding a newborn or young infant
• Diagnosed with heart failure or at high risk of heart failure hospitalization (avoid saxagliptin specifically)
• Over age 60 with prior skin blistering conditions or immunosuppression that might mask or worsen bullous pemphigoid
• Using oral high-dose estrogen therapy with pre-existing hypertriglyceridemia (pancreatitis risk is additive)

Pharmacokinetics in Women: What the Data Actually Show

Sex differences in drug metabolism are real, and they are frequently understudied. The cytochrome P450 enzyme CYP3A4, which metabolizes saxagliptin, shows modest sex-based variability. A population pharmacokinetic analysis included in the saxagliptin NDA package found that sex was not a clinically significant covariate for saxagliptin exposure at approved doses. Sitagliptin is renally excreted largely unchanged; renal clearance correlates more with body size and GFR than sex per se.

The honest answer is that most DPP-4 inhibitor pharmacokinetic trials were not powered to detect sex differences, and subgroup analyses by sex are rarely published separately. Clinicians extrapolate from mixed-sex populations to women. When you are a smaller woman with lower muscle mass than average trial participants, your effective exposure at a standard dose may be somewhat higher. Report symptoms at lower intensity thresholds than you might otherwise.

"Women have been consistently underrepresented in cardiovascular outcomes trials for antidiabetic agents, and the DPP-4 inhibitor trials are no exception," noted in a 2020 analysis in the Journal of the American College of Cardiology examining sex-disaggregated data from major diabetes cardiovascular trials. Women represented between 33% and 38% of enrolled patients in the major DPP-4 inhibitor outcomes trials.

Drug Interactions Women Are Most Likely to Encounter

Oral Contraceptives

No clinically meaningful pharmacokinetic interaction exists between DPP-4 inhibitors and combined oral contraceptives. Ethinyl estradiol and progestin-based formulations do not significantly alter DPP-4 inhibitor exposure.

Hormone Therapy

Similarly, standard-dose estrogen and progesterone hormone therapy formulations used in menopause do not require DPP-4 inhibitor dose adjustments. The main practical point is monitoring: oral estrogen raises triglycerides in some women, and hypertriglyceridemia is a risk factor for pancreatitis. Check a fasting lipid panel within three months of starting oral hormone therapy in any woman on a DPP-4 inhibitor.

Antifungals and CYP3A4 Inhibitors

Saxagliptin specifically requires dose reduction to 2.5 mg daily when co-administered with strong CYP3A4 inhibitors such as ketoconazole, itraconazole, clarithromycin, or atazanavir. Women being treated for recurrent vulvovaginal candidiasis with systemic azole antifungals who also take saxagliptin should alert their prescriber to this interaction. The saxagliptin prescribing information specifies the 2.5 mg dose cap with strong inhibitors.

Practical Storage and Handling

These are standard oral tablets without any cold-chain requirements. Store at room temperature between 68 and 77 degrees Fahrenheit (20 to 25 degrees Celsius). No special handling precautions apply for caregivers, household contacts, or pregnant partners, because these drugs are not cytotoxic or hormonally active in the same category as drugs like cyclophosphamide or estrogens.

Tablets should not be split or crushed unless the prescribing information specifically allows it; splitting can affect absorption rates for some extended-release formulations.

Dispose of unused tablets through an FDA-approved drug take-back program. The DEA maintains a list of authorized collectors; for DPP-4 inhibitors not on that list, the FDA's flush list does not apply, so take-back is the preferred method.